Male Adenoid Cystic Carcinoma of the Breast

Jie Xiao Li, Xi Meng Zhang, Yun Xiao Xiao, Zi Mei Tang, Tao Huang, Jie Ming

1277 Jiefang Avenue, Wuhan 430022, China. Email: mingjiewh@126.com and huangtaowh@163.com

Abstract

Adenoid cystic carcinoma (ACC) of the breast, a rare malignancy that makes up less than 0.1% of all breast malignancies, is much rarer in males than in females. Due to the rarity of this disease, an optimal treatment strategy for male breast ACC has not been established, and therapy for male patients is currently based on guidelines for female patients. According to previous reported cases, some authors believe that male breast ACC may have higher invasive potential than female breast ACC and the prognoses in male patients may be worse than those in female patients. Therefore, a more proactive diagnosis and treatment regimen may be required. However, the clinical feature of our case is inconsistent with this view. Herein we report the case of a 24-year-old male without any antecedent medical or family history who presented with a slow-growing lump on his left chest wall for 5 years. The patient initially underwent lumpectomy, and the mass was pathologically diagnosed as breast ACC. Systemic examination was performed, and no evidence of distant metastasis was found. Then, he received modified radical mastectomy and ipsilateral axillary lymph node dissection. The mastectomy pathological examination revealed that no cancerous tissue was detected around the primary tumor bed, and all 22 axillary lymph nodes were negative. The patient did not receive postoperative chemotherapy, radiotherapy or endocrine therapy and remained well after 28 months of follow-up. In this study, we review the literature and summarize the clinical manifestations, imaging and histopathological characteristics, treatments and outcomes of male breast ACC. We share our experience in the hopes that this evidence will aid in the development of better therapeutics.

Keywords: Adenoid cystic carcinoma; Breast; Male; Treatment; Prognosis; Case report

Introduction

Adenoid cystic carcinoma (ACC) was first discovered by Rob-
In May 2019, the mass had grown to 1.3 × 0.7 cm in size and was hypoechoic with a clear margin and uneven internal echo (Fig. 1b). Therefore, the patient underwent lumpectomy in May 2019. According to the pathological examination results, the mass was described as a biphasic tumor composed of glandular epithelial cells and myoepithelial cells arranged in a tubular, cribriform, solid structure, which supports the diagnosis of breast ACC (Fig. 2). Immunohistochemical staining showed that the tumor cells were negative for ER, PR and HER-2 and positive for E-cadherin, P120-catenin, P63, CK5/6, and CD117. Approximately 20% of the cells expressed Ki67. Then the patient immediately returned to the Department of Breast and Thyroid Surgery for further treatment and received a breast ultrasound and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET-CT). The breast ultrasound revealed a 1.8 × 0.9 cm hypoechoic area under the areola of the left breast (possible postoperative change) (Fig. 1c). Lymph nodes were visible in the bilateral axilla and left clavicle, and an enlarged lymph node approximately 2.3 × 0.6 cm in size was observed in the left axilla (Fig. 1d). The 18F-FDG PET-CT revealed a disordered subcutaneous structure in the left breast region accompanied by increased metabolism, indicating postoperative changes. Small lymph nodes with low metabolism were found in the bilateral neck and axilla. No significant metabolic abnormalities were observed anywhere else in the patient (Fig. 3).

**Treatment**

Based on the breast ultrasound, 18F-FDG PET-CT, pathological examination and the preference of the patient, we performed modified radical mastectomy and left axillary lymph node dissection in June 2019. After the surgery, the patient did not receive subsequent radiotherapy, chemotherapy or endocrine therapy.

**Follow-up and outcomes**

Mastectomy histopathological examination showed no residual carcinoma tissue around the primary tumor bed in the left breast. No vascular tumor embolus was evident by pathological analysis. No nerve invasion was detected, and the surgical margin was negative. None of the 22 ipsilateral axillary lymph nodes resected showed metastatic carcinoma. The patient recovered well and was discharged 1 week later. The patient remained healthy over 28 months of regular follow-up, with no signs of local relapse or distant metastases (Supplementary Figure 1).
Discussion

The incidence of breast ACC is very low, comprising less than 0.1% of all breast carcinomas [4]. Therefore, male breast ACC is very rare; indeed, there have been only 17 reported cases since 1969 [5-20]. Of these, nine cases were reported within the past decade, which may indicate a trend toward increased incidence [13-20]. The susceptibility of various racial subpopulations to breast ACC is currently unknown, though a previous report indicated that black females have a lower incidence rate than white females [21]. Interestingly, eight out of 12 male cases reported in the past 30 years were reported in Asia [12-17, 19]. The median age of breast cancer onset is somewhat higher in males (about 67 years) than females (about 62 years) [22]. The incidence of breast cancer is positively correlated with age in both males and females [22]. The incidence of breast cancer is positively correlated with age in both males and females [22]. The age of onset for male breast ACC is lower (median 41.5 years) than that seen in male breast cancer patients (Table 1 [5-20]). For female breast ACC patients, the median age of onset is 58 - 66 years old [21, 23-26]. The case we report here is from a 24-year-old male.

The dominant manifestation of breast ACC in males is a hard palpable subareolar mass that may be accompanied by pain or tenderness. Other symptoms include skin ulcers and nipple retraction [11, 12, 17]. Nipple discharge has not been reported in any of the available cases. Distant metastases have also been reported as an initial symptom [15, 20]. In female breast ACC, masses are usually detected shortly before seeking medical care [27]. However, due to insufficient awareness of male breast diseases, male patients typically report that their mass has been present for several years by the time of diagnosis [27]. Breast ACC usually appears to be unifocal but can occasionally be multifocal. There is no significant difference in incidence between the left and right breasts [21]. For male patients, no bifocal or multifocal cases have been reported. Tumor size is generally larger in male breast cancer patients than in female patients [28], which is consistent with the data collected from male and female breast ACC patients. The mean tumor diameter in female breast ACC patients is 1.8 - 2.2 cm [3, 21, 29] and the median is 1.8 - 2.2 cm [21, 23]. In male breast ACC patients, the reported mean tumor size is 1.2 - 5 cm and the median is 2.6 cm (Table 1). The tumor in this case
measured only 1.3 cm, which is smaller than the average.

Due to the rarity of the disease, the imaging features of male breast ACC have not been well described. Compared with female breast ACC patients, male cases have very similar nonspecific ultrasonic characteristics, including clear or indistinct boundaries, irregular shapes, and hypoechoic and heterogeneous masses [15, 16, 19, 30]. On mammography, female breast ACC often manifests as an irregular, lobulated, heterogeneous mass with indistinct or microlobulated edges [30]. However, the dominant features in males are spiculated shadows in the subareolar area [16]. Thus far, magnetic resonance imaging (MRI) features of male breast ACC have only been mentioned by Pang et al and include oval nodules, spiculated edges, T1WI hypointensity, and T2WI hyperintensity. Dynamic contrast-enhanced MRI time intensity curves have revealed that tumor enhancement is fast and is followed by a plateau [19]. In female breast ACC cases, the common features include T2 hyperintense in large foci and T2 equal intense in small foci [31, 32]. However, the tumor in this case was 1.2 cm in diameter with T2WI hyperintensity, which is quite different from the characteristics seen in female cases [19].

Unique histopathological features are the major evidence used to diagnose breast ACC. Breast ACC is a kind of biphasic tumor composed of basaloid and luminal epithelial cells. The histological features are similar to those of salivary gland ACC. The tumor cells are distributed around small cysts, forming both true glands and pseudoglandular spaces containing eosinophilic basement membrane material and basophilic mucin. The cells may show cribriform, tubular, or solid growth patterns, either alone or in combination [4, 27, 32]. However, unlike salivary gland ACC, breast ACC rarely features nerve infiltration [33]. Ro et al first classified breast ACC into three grades based on the ratio of solid components within the lesion. Grade I indicates no solid growth. In grade II tumors, the proportion of solid growth is less than 30%, while in grade III tumors, the proportion is more than 30% [34]. Ro et al also proposed that grade II and III tumors are larger in size and are more prone to relapse [34], though this remains controversial [4]. Breast ACC has similar immunohistochemical characteristics to basal-like breast cancer and is often negative for ER, PR and HER-2 [29]. However, other studies have reported ER and PR expression in 0-46% and 0-36% of breast ACC patients, respectively [21, 23, 24, 29, 35]. All of the reported male cases were negative for PR, though two cases were weakly positive for ER [12, 16]. In the dual-cell population of breast ACC, glandular epithelial cells express cytokeratin (CK)7, CK8/18, epithelial membrane antigen (EMA)
and CD117 (C-kit). Fodrin, E-cadherin and β-catenin are usually expressed. Myoepithelial cells are immunoreactive for CK5/6, CK14, CK17, P63, smooth muscle actin (SMA), calponin, and vimentin [4, 27]. The Ki67 index ranges from 4% to 70%, and is higher in tumors with solid components (grade II-III) than in tumors without solid components (grade I) [27]. In our case, the tumor would be histologically classified as grade II with a Ki67 index of 20%, a typical ER/PR/HER-2 triple-negative genotype and a biphasic pattern of epithelial cells (CD117 positive) and myoepithelial cells (P63, CK5/6 positive).

Unlike basal-like/triple-negative breast cancer or salivary gland ACC, which are aggressive, female breast ACC usually has more favorable biological characteristics and prognosis. Previous studies have reported that the axillary lymph node metastasis rate is 0-5.1% [3, 21, 23-25, 29], the local recurrence rate is 0-13% [23, 33], the distant metastasis rate is 0.3-13% [3, 21, 23, 24, 33], and the 10-year survival rate is 86-94% [3, 21, 23, 25, 33, 35]. To date, the prognosis of male breast ACC is still obscure. Among the reported cases of male breast ACC, three (21.4%) had lymph node metastasis, two (15.4%) had local recurrence, and three (23%) had distant metastasis.

The majority of the eight cases with no relapse had a follow-up period significantly shorter than the median follow-up time of female patients (59 - 84 months) [23, 24, 33, 35]. Moreover, Millar et al mentioned in their retrospective study that a 53-year-old male ACC patient died from lung, bone and abdominal metastases 7 months after receiving a simple mastectomy and adjuvant radiotherapy [26]. Therefore, some authors consider that male breast ACC may be more aggressive and have poorer prognosis than female [16, 17, 19]. Nevertheless, there are insufficient data to support this speculation.

Surgery is the main treatment option for breast ACC [31]. Most female patients receive breast-conserving surgery. Since axillary lymph node metastasis is rare, routine axillary lymph node dissection is generally considered unnecessary for female breast ACC [23-25, 29]. For the use of adjuvant radiotherapy, there is no universal standard for the use of adjuvant radiotherapy. However, several studies have reported positive surgical margins after breast-conserving therapy [28]. Moreover, other studies have demonstrated that adjuvant radiotherapy is effective at improving overall and disease-specific survival rates in female patients [35, 36]. Therefore, postoperative ad-

| References | Year | Age | Diameter | Node | Surgery | Adjuvant treatment | Outcome of follow up |
|------------|------|-----|----------|------|---------|-------------------|----------------------|
| Presenting case | 2021 | 23 | 1.3 cm | Neg | LM → MRM + ALND | None | Remain well after 24 months of follow-up |
| Hogan and Fan [20] | 2020 | 60 | 2.1 cm | NR | LM | Radiotherapy | Lung metastasis |
| Pang et al [19] | 2019 | 44 | 1.2 cm | Neg | LM → MRM + ALND | Postoperative chemotherapy | Remain well after 26 months of follow-up |
| Douglas and Mackenzie [18] | 2019 | 21 | 5.0 cm | Neg | ScM → SM + SNB | None | Remain well after 12 months of follow-up |
| Zadeh et al [17] | 2017 | 42 | 4.0 cm | Neg | MRM + ALND | None | Remain well after 12 months of follow-up |
| Tang et al [16] | 2015 | 19 | 3.0 cm | Neg | RM + ALND | Endocrine therapy | Remain well after 67 months of follow-up |
| Yoo et al [15] | 2013 | 41 | 1.7 cm | Pos | NR | None | Bone and lung metastasis |
| Sahan et al [14] | 2012 | 60 | 1.3 cm | NR | LM → RM | None | NR |
| Liu et al [13] | 2012 | 20 | 2.1 cm | Neg | SM + SNB | None | NR |
| Kshirsagar et al [11] | 2006 | 82 | 3/5 | Pos | MRM + ALND | Radiotherapy | Recurrence at 2 years |
| Maciag et al [12] | 2006 | 80 | 1/10 | Pos | LM → SM + ALND | Radiotherapy + endocrine therapy | Remain well after 5 years of follow-up |
| Miliauskas et al [10] | 1991 | 13 | 3.8 cm | Neg | LM → ScM | None | Remain well after 30 months of follow-up |
| Hjorth et al [9] | 1977 | 21 | 3.8 cm | Neg | SM | None | Remain well after 2 years of follow-up |
| Ferlito et al [8] | 1974 | 60 | NR | Neg | SM | None | NR |
| Verani et al [7] | 1973 | 78 | 3.5 cm | Neg | MRM + ALND | None | Lung metastasis |
| Woyke et al [6] | 1970 | 37 | NR | Neg | LM | None | Recurrence at 5 and 7 years |
| Ferlito [5] | 1969 | Middle aged | NR | NR | NR | NR | NR |

Neg: negative; Pos: positive; NR: no report; LM: lumpectomy; MRM: modified radical mastectomy; ALND: axillary lymph node dissection; ScM: subcutaneous mastectomy; SM: simple mastectomy; SNB: sentinel node biopsy; RM: radical mastectomy.
juvant radiotherapy is recommended in most studies [35-37].
Chemotherapy and endocrine therapy are infrequently used for
the treatment of breast ACC. Only 11% and 8% of female pa-
tients received adjuvant chemotherapy and endocrine therapy,
respectively [29]. Except for the cases reported by Woyke et al
and Hogan et al in 1970 and 2020 [6, 20], most (13 of 15) male
patients underwent simple mastectomy or modified radical
mastectomy [7-14, 16-19]. Ipsilateral axillary lymph node dis-
section was performed in seven out of the 15 men [7, 11, 12, 16,
17, 19], and sentinel lymph node biopsy was performed in two
cases [13, 18]. Three patients received adjuvant radiotherapy;
in one case the radiotherapy was performed following wide
resection of a locally recurrent lesion [11, 12, 20]. One patient
underwent postoperative chemotherapy with cyclophospha-
mide, epirubicin, and docetaxel, and two patients with weak
immunoreactivity for ER received endocrine therapy [12, 16,
19]. In the case reported here, the patient initially underwent
lumpectomy, and the tumor was pathologically diagnosed as
breast ACC. After taking the potentially aggressive biological
behavior of male breast ACC into consideration and respecting
the patients’ wishes, we performed modified radical mastec-
tomy and axillary lymph node dissection. However, pathologi-
cal examination revealed that there was no cancerous tissue
around the primary tumor bed, all 22 axillary lymph nodes
were negative, and there was no perineural or lymphovascular
invasion. From the limited data mentioned above, although the
axillary lymph node metastasis rate of breast ACC in males is
slightly higher than that in females, the axillary lymph nodes in
most reported male patients are still negative (Table 1). There-
fore, axillary lymph node dissection may be unnecessary for
male breast ACC and routine sentinel lymph node biopsy may
be a better option. The patient did not undergo adjuvant radio-
therapy or chemotherapy after surgery. In addition, a multi-
institutional study of breast ACC reported that the median time
to locoregional recurrence and distant metastasis was 48 and
25.5 months, respectively. The longest time to local recurrence
or distant relapse was 161 months [38]. Therefore, we recom-
ended that our patient undergo regular follow-ups at 3 - 6
month intervals for the first 2 years and then every year for at
least 10 years. The patient remained in good condition with no
recurrence during a 28-month follow-up period.

In conclusion, breast ACC is a rare malignant neoplasm with
an excellent prognosis. Its epidemiological characteristics, clin-
cal manifestations, imaging characteristics, biological features,
prognosis and treatment regimens may vary between sexes. Ac-
cording to previous reports, the prognosis of male breast ACC
may be worse than female patients due to potentially aggressive
behavior and the neglect of the disease. However, whether to
choose a more radical treatment strategy for male breast ACC
than female patient remains to be determined due to lack of
clinical data. More long-term follow-up studies are necessary to
determine the optimal treatment protocol of male breast ACC.

Acknowledgments

None to declare.

Financial Disclosure

This report received no specific grant from any funding agency
in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors have no conflict of interest to disclose.

Informed Consent

Written informed consent for publication of his clinical details
and/or clinical images was obtained from the patient.

Author Contributions

Li JX reviewed the literature and drafted the manuscript;
Huang T and Ming J conceived and designed this case report
and revised the manuscript; Zhang XM was the patient’s at-
tending surgeon and helped draft the paper; Xiao YX and Tang
ZM contributed to the literature review and manuscript draft-
ing; all authors read and approved the final version of the sub-
mitted manuscript.

Data Availability

The authors declare that data supporting the findings of this
study are available within the article.

Abbreviations

ACC: adenoid cystic carcinoma; ER: estrogen receptor; PR:
progesterone receptor; HER-2: human epidermal growth fac-
tor receptor 2; 18F-FDG PET-CT: 18F-fluorodeoxyglucose pos-
itron emission tomography/computed tomography; CK: cy-
tokeratin; EMA: epithelial membrane antigen; SMA: smooth
muscle actin

References

1. Cantu G. Adenoid cystic carcinoma. An indolent but ag-
gressive tumour. Part A: from aetiopathogenesis to diag-
nosis. Acta Otorhinolaryngol Ital. 2021;41(3):206-214.
2. Geschickter CF, Copeland MM. Diseases of the breast:
diagnosis, pathology, treatment. Philadelphia: J.B. Lip-
pincott; 1945.

Supplementary Material

Suppl 1. Timeline of the male breast ACC case. ACC: adenoid
cystic carcinoma.

Suppl 1. Timeline of the male breast ACC case. ACC: adenoid
cystic carcinoma.
2010;102(4):342-347.  
37. Boujelbene N, Khabir A, Boujelbene N, Jeanneret Sozzi W, Mirimanoff RO, Khanfir K. Clinical review—breast adenoid cystic carcinoma. Breast. 2012;21(2):124-127.  
38. Slodkowska E, Xu B, Kos Z, Bane A, Barnard M, Zubovits J, Iyengar P, et al. Predictors of outcome in mammary adenoid cystic carcinoma: a multi-institutional study. Am J Surg Pathol. 2020;44(2):214-223.